Trending...
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- California: Crime is down in San Francisco, key law enforcement partnerships yield successful results
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company's common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on The Californer
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on The Californer
- California: TOMORROW: Governor Newsom to discuss the economic advancement and growth of the state
- California: Governor Newsom to Trump: We're suing immediately if you send troops into San Francisco
- Long Beach: City to Host Neighborhood Halloween Carnival at Silverado Park
- Altadena Mountain Rescue Team Recognized with 2025 ReadyCommunities Partnership National Service Award For Determination and Resilience
- Long Beach to Host Urban Forest Plan Kickoff Meeting
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Filed Under: Business
0 Comments
Latest on The Californer
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- The Swig Company Presents:Re-Discovering Native America: Stories in Motion with The Red Road Project
- California: Governor Newsom honors fallen La Mesa Police Department Officer
- HollywoodActorJobs.com Full-Time Employment Infomercial World Premiere 10/22/25 at Harkins Theatres
- Required Reading for Every Business in The Universe! Read this book about this Marketing Math Today!
- California's Cannabis Task Force Seizes and Eradicates Over $222 Million in Illegal Cannabis in Q3 2025
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"
- CCHR Exposes Conflicted Psychiatrists Behind Teen Antidepressant Surge
- Governor Newsom announces tax credit awards for new job-creating films shooting in California and generating $1.4 billion for the state's economy
- Near Zero NOx Achieved With Proven Emissions Reduction Technology at Two California Food Facilities
- Escondido's Stevie Gonzales Inspires in 'Baby of the Year' Contest — Born with Down Syndrome and a Heart Condition
- WIBO Announces Fall 2025 Entrepreneurship Programs to Empower NYC Founders and Small Business Owners
- California: Governor Newsom announced as co-chair for the COP30 Local Leaders Forum in Rio de Janeiro
- Local College Student Launches "Cleopatra" App to Make Cleaning Easy for Mercer County Residents
- Wohler announces release of additional Balance Control output tracking for its eSeries in-rack monitor range
- The Best Cartier Dupe Bracelets to Buy in 2025
- A Milestone of Giving: Ten Percent Group Donates £25,000 to Cure Parkinson's
- Suicide Commando Ignites DNA Lounge in a Night of Industrial Euphoria
- Tami Goveia Enters FabOver40, Inspiring Hollywood Legacy for Breast Cancer Cause
- Trump shutdown could soon halt food support for millions in California; CalFresh cards face possibility of no new funds in November